Browse the toolkit beneath workflows. The mechanism branch runs mechanism -> architecture -> component, while the technique branch runs from high-level approaches down to concrete methods.
10 items matching 1 filter
Mechanism Branch
Layer 1
Mechanisms
Top-level concepts: biophysical action modes such as heterodimerization, photocleavage, or RNA binding.
Layer 2
Architectures
Arrangements that realize or deploy mechanisms, including switches, construct patterns, and delivery strategies.
Layer 3
Components
Low-level parts and sequence-defined elements used inside architectures, including protein domains and RNA elements.
Technique Branch
Layer 1
Approaches
High-level engineering practices such as computational design, directed evolution, sequence verification, and functional assay.
Layer 2
Methods
Concrete methods used to design, build, verify, or characterize engineered systems.
Showing 1-10 of 10
This review focuses on blood cell membrane-derived nanocarriers as drug delivery and immune-regenerative platforms.
Among the various membrane sources, those derived from blood cells such as red blood cells, platelets, and leukocytes offer distinctive advantages, including immune evasion, prolonged systemic circulation, and selective tissue targeting.
Nanotherapeutics based on platelet membranes represent a new and advanced biomimetic approach in nanomedicine. By covering synthetic nanoparticle cores with natural platelet membranes, these platforms ingeniously combine the multifaceted biointerfacing abilities of platelets, such as long circulation, immune evasion, and targeting of inflamed tissues, with the many functions of engineered cores.
Platelet membrane-coated nanoparticles, extracellular vesicles, microbubbles, microemulsions, as well as platelet membrane vesicles and their derivatives have shown significant promise for I/RI treatment.
Platelet membrane-coated nanoparticles, extracellular vesicles, microbubbles, microemulsions, as well as platelet membrane vesicles and their derivatives have shown significant promise for I/RI treatment.
Platelet membrane-coated nanoparticles, extracellular vesicles, microbubbles, microemulsions, as well as platelet membrane vesicles and their derivatives have shown significant promise for I/RI treatment.
Among the various membrane sources, those derived from blood cells such as red blood cells, platelets, and leukocytes offer distinctive advantages, including immune evasion, prolonged systemic circulation, and selective tissue targeting.
Platelet membrane-coated nanoparticles, extracellular vesicles, microbubbles, microemulsions, as well as platelet membrane vesicles and their derivatives have shown significant promise for I/RI treatment.
The red blood cell (RBC-EVs) extracellular vesicles can serve as a solution to this issue since they are biocompatible, long-term stable, and with low immunogenicity.
Among the various membrane sources, those derived from blood cells such as red blood cells, platelets, and leukocytes offer distinctive advantages, including immune evasion, prolonged systemic circulation, and selective tissue targeting.